Clinical characteristics and outcomes of cardiomyopathies related to immune-mediated diseases

Further Publications

Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy

JAMA Cardiol

Hafeez N, Claggett BL, Owens AT, Helms AS, Saberi S, Lampert R, Stendahl JC, Ashley EA, Parikh VN, Lakdawala NK, Ingles J, Olivotto I, Ho CY, Taylor MR, Khan SS, Day SM

doi: 10.1001/jamacardio.2025.4869

Further Publications

Location of LMNA Variants and Clinical Outcomes in Cardiomyopathy

JAMA Cardiol

Bhaskaran A, Ben Yaou R, Helms AS, Fayssoil A, Richard P, Stojkovic T, Anselme F, Labombarda F, Chikhaoui C, De Sandre-Giovannoli A, Jeru I, Leturcq F, Vigouroux C, Dembele M, Elliott P, Savvatis K, Zeppenfeld K, Bouguerra H, Charron P, Kumar S, Bonne G, Wahbi K, Lakdawala NK

doi: 10.1001/jamacardio.2025.2069

Cardiovascular Risk and DiseasesFurther Publications

Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction

JAMA Cardiol

Ridker PM, Baeres FMM, Hveplund A, Engelmann MMD, Hovingh GK, Lincoff AM, Marx N, Navar AM, Sattar N, Tuttle K, Perkovic V

doi: 10.1001/jamacardio.2025.4491

Heart, Artery and Coronary Diseases

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Am Heart J

Steg PG, Nicolas J, Baber U, Sartori S, Zhang Z, Feng Y, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dangas G, Dudek D, Escaned J, Gibson CM, Han YL, Huber K, Kastrati A, Kaul U, Marx SO, Kornowski R, Kunadian V, Vogel B, Oliva A, Mehta SR, Moliterno D, Sardella G, Krucoff M, Shlofmitz RA, Sharma S, Pocock S, Mehran R

doi: 10.1016/j.ahj.2025.01.016

Heart Failure

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

PLoS One

Bitos K, Laptseva N, Haider T, Rossi VA, Nägele MP, Barthelmes J, Ruschitzka F, Sudano I, Flammer AJ

doi: 10.1371/journal.pone.0325668

Heart, Artery and Coronary Diseases

Ten-Year Clinical Outcomes and Cause of Death in Patients on Dialysis Undergoing Percutaneous Coronary Intervention: A Retrospective Mayo Clinic PCI Registry Analysis

Mayo Clin Proc

Nagaraja V, Lewis BR, Korsapati H, Mene-Afejuku TO, Dillon JJ, Cheungpasitporn W, Gharacholou M, Reeder G, Hibbert B, Best P, Prasad A, Singh M

doi: 10.1016/j.mayocp.2025.11.016

Atrial Fibrillation

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

J Am Coll Cardiol

Galea R, De Marco F, Aminian A, Meneveau N, Chalkou K, Anselme F, Gräni C, Franzone A, Vranckx P, Fischer U, Valgimigli M, Räber L

doi: 10.1016/j.jacc.2025.03.535

Heart, Artery and Coronary Diseases

Reproductive Health Outcomes of Congenital Heart Disease Survivors: A Report from the Congenital Heart Disease Project to Understand Lifelong Survivor Experience (CHD PULSE Study)

Am Heart J

Erdem S, Shi CY, Schwartz AD, Flores J, Knight J, Aldoss O, Anderson SC, Canter CE, Hiremath G, Hussain T, John AS, Marino BS, McHugh KE, Raghuveer UG, Spector LG, Louis JDS, Kochilas L, Oster ME, Gaitonde M

doi: 10.1016/j.ahj.2025.107338

Heart Failure

Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial

JAMA

Lopes RD, Bocchi EA, Echeverría LE, Demacq C, de Barros E Silva PGM, Barbosa LM, Damiani L, Sayyed S, Yoshida LAF, Furtado RHM, Morillo CA, Kevorkian R, Ramires F, Bahit MC, Magaña A, Chávez-Mendoza A, Miguel da Silva AH, Coelho da Silva A, Freitas AF Jr, Romano AA, Parneix A, Segura A, França CCB, Botta CE, de Barros E, Perna ER, Montenegro E, Quiroz Diaz FR, Feitosa-Filho GS, Severini GV, Molina I, Miranda JDSS, Sala J, Kerr Saraiva JF, Carbajales J, Maia LN, Santana Passos LC, Simões MV, Moreira MDCV, Nunes MCP, Hernandes ME, Hominal M, Zarandon RS, Leon de la Fuente R, Aras R, Bazan SGZ, Luiz da Silva T Jr, Madrini V, de Oliveira WA Jr, Saporito WF, Gimpelewicz C, McMurray JJV, Prevention and Reduction of Adverse Outcomes in Chagasic Heart Failure Trial Evaluation (PARACHUTE-HF) Investigators

doi: 10.1001/jama.2025.19808

Related content

Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy

Location of LMNA Variants and Clinical Outcomes in Cardiomyopathy

Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

Ten-Year Clinical Outcomes and Cause of Death in Patients on Dialysis Undergoing Percutaneous Coronary Intervention: A Retrospective Mayo Clinic PCI Registry Analysis

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

Reproductive Health Outcomes of Congenital Heart Disease Survivors: A Report from the Congenital Heart Disease Project to Understand Lifelong Survivor Experience (CHD PULSE Study)

Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial